Brazilian Researchers Identify Amazon Scorpion Venom Peptide with Promising Anti-Breast Cancer Activity
核心洞察
Researchers at the University of São Paulo (搜索) have identified a peptide called BamazScplp1 (搜索) from Amazon scorpion Brotheas amazonicus (搜索) venom that shows anti-tumor activity against breast cancer (搜索) cells.
Laboratory tests demonstrated that the peptide's impact on breast cancer (搜索) cells was comparable to paclitaxel, a commonly prescribed chemotherapy treatment, primarily triggering necrosis.
The discovery is part of a broader bioprospecting collaboration between Brazilian institutions to develop venom-derived biopharmaceuticals for various medical applications.
Researchers at the University of São Paulo (搜索)'s Ribeirão Preto School of Pharmaceutical Sciences (FCFRP-USP) have identified a promising anti-cancer peptide from the venom of Brotheas amazonicus (搜索), an Amazon scorpion species, that demonstrates activity against breast cancer (搜索) cells comparable to established chemotherapy treatments.
The molecule, designated BamazScplp1 (搜索), was discovered through a collaborative bioprospecting effort involving scientists from the National Institute for Amazonian Research (搜索) (INPA) and the Amazonas State University (搜索) (UEA). Laboratory testing revealed that the peptide's impact on breast cancer (搜索) cells was comparable to paclitaxel, a widely prescribed chemotherapy medication.
Mechanism of Action and Therapeutic Potential
The scorpion-derived peptide primarily triggers necrosis, a form of cell death that has been previously associated with molecules from other scorpion species. "Through bioprospecting, we were able to identify a molecule in the species of this Amazonian scorpion that is similar to that found in the venoms of other scorpions and that acts against breast cancer (搜索) cells," said Eliane Candiani Arantes, a professor at FCFRP-USP and coordinator of the project.
The research findings were presented during FAPESP Week France in the Occitanie region of southern France, highlighting the international significance of this discovery in the field of venom-derived therapeutics.
Broader Venom-Based Drug Development Program
This breakthrough is part of a comprehensive research program at FCFRP-USP and partner institutions focused on cloning and expressing bioactive molecules from venomous animals. The team has previously developed other therapeutic applications from venom components, including a patented fibrin sealant described as a "biological glue."
The fibrin sealant is produced from serinoproteinase enzymes extracted from snake venom, including Bothrops neuwiedi pauloensis and Crotalus durissus terrificus, combined with cryoprecipitate enriched with fibrinogen from buffalo, cattle, or sheep. This product has been investigated for nerve repair, bone healing, and restoring movement following spinal cord injury, and is currently undergoing phase three clinical trials.
Manufacturing and Scale-Up Strategy
The research team plans to advance the scorpion peptide discovery through heterologous expression technology. "We also intend to obtain these molecules through heterologous expression," Arantes explained. This approach involves producing the therapeutic molecules in Pichia pastoris yeast, which could enable industrial-scale manufacturing if the compound proves successful in clinical development.
The team has also identified two neurotoxins in scorpion venom with immunosuppressive effects, expanding the potential therapeutic applications of their venom-derived molecule library.
Research Infrastructure and Support
The work is conducted within projects supported by FAPESP and connected to the Center for Translational Science and Development of Biopharmaceuticals (CTS), housed at the Center for the Study of Venoms and Venomous Animals (CEVAP) at São Paulo State University (UNESP) in Botucatu.
The discovery represents a significant advancement in the field of natural product drug discovery, particularly in the development of novel cancer therapeutics from previously unexplored biological sources. The comparable efficacy to paclitaxel suggests potential for clinical development, though further studies will be needed to establish safety profiles and optimal dosing regimens.